Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy? - Université de Lorraine Access content directly
Journal Articles Gastroenterology Year : 2014

Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?

Abstract

We read with great interest the paper by Panes et al1 regarding the efficacy of early azathioprine (AZA) therapy in early Crohn’s disease (CD). The “AZathioprine for Treatment or Early Crohn’s disease in adults” (AZTEC) study was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial conducted in 31 Spanish hospitals over 3 years. The authors developed a randomized placebo-controlled trial in very early CD patients (<8 weeks of diagnosis) without bowel damage (symptomatic stenotic, penetrating, or perianal disease).

Dates and versions

hal-01687303 , version 1 (18-01-2018)

Identifiers

Cite

Peter Lakatos, Laurent Peyrin-Biroulet. Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?. Gastroenterology, 2014, 146 (3), pp.867 - 868. ⟨10.1053/j.gastro.2013.11.053⟩. ⟨hal-01687303⟩
14 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More